Castleark Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Castleark Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,240	Closed	-$196K	–	339
2020 Q4	$196K	Hold	2,240	–	–	0.01%	308
2020 Q3	$170K	Sell	2,240 -3,060	-58%	-$310K	0.01%	313
2020 Q2	$654K	Buy	5,300 +3,190	+151%	+$317K	0.03%	237
2020 Q1	$178K	Buy	+2,110	New	+$182K	0.01%	284
2015 Q3	–	Sell	-38,250	Closed	-$5.23M	–	369
2015 Q2	$5.23M	Buy	38,250 +2,250	+6%	+$279K	0.14%	179
2015 Q1	$4.49M	Sell	36,000 -2,150	-6%	-$228K	0.11%	206
2014 Q4	$3.45M	Buy	+38,150	New	+$3.17M	0.09%	190
2013 Q3	–	Sell	-1,125	Closed	-$63K	–	351
2013 Q2	$63K	Buy	+1,125	New	+$70.1K	﹤0.01%	310

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Castleark Management's BMRN Position: Q1 2021 in Review

Castleark Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 2,240 shares — an estimated $196K sold.

Castleark Management first reported a position in BMRN in Q2 2013 and held it in 8 quarters. The position peaked at $5.23M in Q2 2015. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Castleark Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Castleark Management sold 2,240 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $196K.
Castleark Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Castleark Management's BioMarin Pharmaceuticals position peaked at $5.23M in Q2 2015.
530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Castleark Management's 13F filing for Q1 2021, filed 14 May 2021.